Despite efforts by test maker Grail to highlight outcomes the company considers positive, some experts are warning against using the Galleri test and others like it.

Advancing Research, Awareness, and Targeted Youth Advocacy for Women Diagnosed with Breast Cancer Before Age 40 DENVER, ...

Shares in the company lost about half their value in Friday trading after the clinical trial failed to demonstrate a statistically significant reduction in stage III and IV cancers.

Another challenge facing test designers is that early detection may not necessarily save lives. A crucial factor, and something that is still unknown about the new multi-cancer tests, is whether they ...

MADISON, Wis., September 10, 2025 — Exact Sciences Corp. (Nasdaq: EXAS), a leader in cancer diagnostics, today announced the launch of the Cancerguard™ test, a new multi-cancer early detection (MCED) ...

A bipartisan bill to ensure Medicare covers multi-cancer early detection tests has advanced in the U.S. House. The bill would allow Medicare to cover FDA-approved MCED screenings, which can detect ...

Use of annual supplemental multi-cancer early detection testing led to a 45% decrease in stage IV diagnoses, relative to standard of care, in a modeling study. The largest absolute reductions in stage ...

Each year, approximately 36,000 people are diagnosed with the disease in the United States, according to the American Cancer ...

The company will offer access to Galleri®, an innovative blood test from GRAIL, Inc. that screens for more than 50 types of cancer Today, Hims & Hers Health, Inc. (NYSE: HIMS), the leading digital ...